Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to personalize care for rare blood disorders

NCT ID NCT07206095

Knowledge-focused Sponsor: Hospital Universitari Vall d'Hebron Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with sickle cell disease or other rare anemias. Researchers want to use advanced genetic and blood tests to better understand each person's condition. The goal is to make diagnosis more precise so that treatments can be tailored to each patient. About 200 participants will join this research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia: * Sickle cell disease * Thalassemic syndromes * Congenital dyserythropoietic anemia * Enzymopathy * Unstable Hemoblogin / Altered oxygen affinity * Hereditary stomatocytosis * Hereditary pyropoikilocytosis * Hereditary spherocytosis with severe anemia (\<8 g/dL) or inconclusive diagnosis: * Patient with chronic hemolytic anemia and red cell smear compatible, but with: * EMA binding test: inconclusive or negative * Genetic testing: no definitive diagnosis (VUS or no findings) * Not transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included. Exclusion Criteria: * Carrier traits in autosomal recessive hereditary anemias

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia due to membrane defect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia anemia due to enzyme disorder anemia, nonspherocytic hemolytic, associated with abnormality of red cell membrane congenital dyserythropoietic anemia disease hemoglobinopathy hereditary spherocytosis hereditary stomatocytosis inherited hemoglobinopathy pyropoikilocytosis, hereditary sickle cell disease thalassemia unstable hemoglobin disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia due to membrane defect Congenital dyserythropoietic anemia (CDA) Enzyme disorder; anemia Hemoglobin disorder Rare anemia disorders Sickle cell disease Spherocytosis, hereditary Stomatocytosis Thalassaemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Consorci Sanitari de Terrassa

    RECRUITING

    Terrassa, Barcelona, 08227, Spain

  • Consorci Sanitari del Maresme - Hospital de Mataró

    RECRUITING

    Mataró, Barcelona, 08304, Spain

  • Hospital General de Granollers

    RECRUITING

    Granollers, Barcelona, 08402, Spain

  • Hospital Sant Joan de Déu

    RECRUITING

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • Hospital Universitari Arnau de Vilanova

    RECRUITING

    Lleida, Lleida, 25198, Spain

  • Hospital Universitari Mútua de Terrassa

    RECRUITING

    Terrassa, Barcelona, 08221, Spain

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, Barcelona, 08035, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Barcelona, 08025, Spain

  • Parc Taulí Hospital Universitari

    RECRUITING

    Sabadell, Barcelona, 08208, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.